Cargando…

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis

Yersinia pestis is a Gram-negative pathogen that causes plague, a devastating disease that kills millions worldwide. Although plague is efficiently treatable by recommended antibiotics, the time of antibiotic therapy initiation is critical, as high mortality rates have been observed if treatment is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gur, David, Chitlaru, Theodor, Mamroud, Emanuelle, Zauberman, Ayelet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823876/ https://www.ncbi.nlm.nih.gov/pubmed/33401634 http://dx.doi.org/10.3390/antibiotics10010040

Ejemplares similares

Host Iron Nutritional Immunity Induced by a Live Yersinia pestis Vaccine Strain Is Associated with Immediate Protection against Plague
por: Zauberman, Ayelet, et al.
Publicado: (2017)

Rapid Induction of Protective Immunity against Pneumonic Plague by Yersinia pestis Polymeric F1 and LcrV Antigens
por: Aftalion, Moshe, et al.
Publicado: (2023)

Novel RNA Extraction Method for Dual RNA-seq Analysis of Pathogen and Host in the Early Stages of Yersinia pestis Pulmonary Infection
por: Israeli, Ofir, et al.
Publicado: (2021)

Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague
por: Levy, Yinon, et al.
Publicado: (2018)

Disruption of the NlpD lipoprotein of the plague pathogen Yersinia pestis affects iron acquisition and the activity of the twin-arginine translocation system
por: Tidhar, Avital, et al.
Publicado: (2019)

Circumventing Y. pestis Virulence by Early Recruitment of Neutrophils to the Lungs during Pneumonic Plague
por: Vagima, Yaron, et al.
Publicado: (2015)

An Improvement in Diagnostic Blood Culture Conditions Allows for the Rapid Detection and Isolation of the Slow Growing Pathogen Yersinia pestis
por: Makdasi, Efi, et al.
Publicado: (2022)

The NlpD Lipoprotein Is a Novel Yersinia pestis Virulence Factor Essential for the Development of Plague
por: Tidhar, Avital, et al.
Publicado: (2009)

Influenza virus infection augments susceptibility to respiratory Yersinia pestis exposure and impacts the efficacy of antiplague antibiotic treatments
por: Vagima, Yaron, et al.
Publicado: (2020)

Early sensing of Yersinia pestis airway infection by bone marrow cells
por: Vagima, Yaron, et al.
Publicado: (2012)

YopP-Expressing Variant of Y. pestis Activates a Potent Innate Immune Response Affording Cross-Protection against Yersiniosis and Tularemia
por: Zauberman, Ayelet, et al.
Publicado: (2013)

Correction: YopP-Expressing Variant of Y. pestis Activates a Potent Innate Immune Response Affording Cross-Protection against Yersiniosis and Tularemia
por: Zauberman, Ayelet, et al.
Publicado: (2014)

Correction: Yopp-Expressing Variant ofY. pestis Activates a Potent Innate Immune Response Affording Cross-Protection against Yersiniosis and Tularemia
por: Zauberman, Ayelet, et al.
Publicado: (2013)

Yersinia pestis Endowed with Increased Cytotoxicity Is Avirulent in a Bubonic Plague Model and Induces Rapid Protection against Pneumonic Plague
por: Zauberman, Ayelet, et al.
Publicado: (2009)

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
por: Mei, Yikun, et al.
Publicado: (2020)

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
por: Feng, Jie, et al.
Publicado: (2014)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria
por: Peyclit, Lucie, et al.
Publicado: (2022)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015)

In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs
por: Elmorsy, Mohammad A., et al.
Publicado: (2021)

Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury
por: Li, Haixia, et al.
Publicado: (2023)

Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation
por: Voss, Linda, et al.
Publicado: (2021)

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses
por: Ding, Cuiling, et al.
Publicado: (2022)

Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model
por: Gur, David, et al.
Publicado: (2018)

Early Diagnosis of Pathogen Infection by Cell-Based Activation Immunoassay
por: Bar-Haim, Erez, et al.
Publicado: (2019)

Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium
por: Gargvanshi, Shivani, et al.
Publicado: (2022)

Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections
por: Keiser, Jennifer, et al.
Publicado: (2016)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Iron-Modified Blood Culture Media Allow for the Rapid Diagnosis and Isolation of the Slow-Growing Pathogen Francisella tularensis
por: Makdasi, Efi, et al.
Publicado: (2022)

A Rapid Antimicrobial Susceptibility Test for Determining Yersinia pestis Susceptibility to Doxycycline by RT-PCR Quantification of RNA Markers
por: Shifman, Ohad, et al.
Publicado: (2019)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Improved production of monoclonal antibodies against the LcrV antigen of Yersinia pestis using FACS-aided hybridoma selection
por: Sittner, Assa, et al.
Publicado: (2018)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens
por: Hind, Charlotte K., et al.
Publicado: (2019)

Virtual Screening of FDA-Approved Drugs against LasR of Pseudomonas aeruginosa for Antibiofilm Potential
por: Sadiq, Suhaib, et al.
Publicado: (2020)

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
por: Liang, Hualou, et al.
Publicado: (2021)

Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague
por: Vagima, Yaron, et al.
Publicado: (2022)

Reporter-Phage-Based Detection and Antibiotic Susceptibility Testing of Yersinia pestis for a Rapid Plague Outbreak Response
por: Moses, Sarit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ulqpd461o2s8235pj7m1v5jg77